-
Article
Open AccessA phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations
This phase I trial was conducted to determine the maximum tolerated dose (MTD) and recommended dose of afatinib for phase II trial in elderly patients with advanced non-small cell lung cancer (NSCLC) harboring...
-
Article
Open AccessReal-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer
Afatinib, a second-generation epidermal growth factor receptor (EGFR)—tyrosine kinase inhibitor (TKI) for mutant non-small cell lung cancer (NSCLC), was approved in Japan in 2014. This study evaluated clinical...
-
Article
Open AccessRescue computed tomography-guided drainage of a giant mediastinal mature teratoma causing airway obstruction prior to surgical resection: a case report
Giant mediastinal mature teratomas may cause airway obstruction or decreased venous return due to the mass effect. Preoperative stabilization of the respiratory and circulatory systems is important for periope...